Promising lupus drug tested in kids shows disease control
NCT ID NCT01649765
First seen Feb 21, 2026 · Last updated May 06, 2026 · Updated 8 times
Summary
This study tested a drug called belimumab in children aged 5 to 17 with active lupus. The goal was to see if adding belimumab to their usual treatment could better control the disease. The trial measured how many kids had less lupus activity after one year. Belimumab is not a cure, but aims to manage lupus symptoms and reduce flare-ups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Phoenix, Arizona, 85016, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20010, United States
-
GSK Investigational Site
Augusta, Georgia, 30912, United States
-
GSK Investigational Site
St Louis, Missouri, 63104, United States
-
GSK Investigational Site
New York, New York, 10032, United States
-
GSK Investigational Site
The Bronx, New York, 10467, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Buenos Aires, C1270AAN, Argentina
-
GSK Investigational Site
Rosario, 2000, Argentina
-
GSK Investigational Site
Santa Fe, 5400, Argentina
-
GSK Investigational Site
Calgary, Alberta, T3B 6A8, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 1X8, Canada
-
GSK Investigational Site
Aichi, 474-8710, Japan
-
GSK Investigational Site
Kagoshima, 890-8520, Japan
-
GSK Investigational Site
Miyagi, 989-3126, Japan
-
GSK Investigational Site
Tokyo, 113-8519, Japan
-
GSK Investigational Site
San Luis Potosí City, 78240, Mexico
-
GSK Investigational Site
Lima, Lima 27, Peru
-
GSK Investigational Site
Lima, Lima 5, Peru
-
GSK Investigational Site
Surco, Lima 33, Peru
-
GSK Investigational Site
Lodz, 91-738, Poland
-
GSK Investigational Site
Warsaw, 02-637, Poland
-
GSK Investigational Site
Moscow, 119435, Russia
-
GSK Investigational Site
Saint Petersburg, 194100, Russia
-
GSK Investigational Site
Tolyatti, 445846, Russia
-
GSK Investigational Site
Espluges de Llobregat, 08950, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
-
GSK Investigational Site
Bristol, BS2 8BJ, United Kingdom
-
GSK Investigational Site
Liverpool, L12 2AP, United Kingdom
-
GSK Investigational Site
London, NW1 2PG, United Kingdom
-
GSK Investigational Site
London, WC1N 3JH, United Kingdom
Conditions
Explore the condition pages connected to this study.